- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05322473
Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
Phase 2, Randomized, Parallel-group, Double-blind, Placebo-controlled Study of Sonelokimab in Patients With Active Moderate to Severe Hidradenitis Suppurativa
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Sofia, Bulgaria, 1407
- Clinical Site
-
Sofia, Bulgaria, 1431
- Clinical Site
-
Sofia, Bulgaria, 1463
- Clinical Site
-
Stara Zagora, Bulgaria, 6000
- Clinical Site
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T3E 0B2
- Clinical Site
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3M 3Z4
- Clinical Site
-
-
New Brunswick
-
Fredericton, New Brunswick, Canada, E3B 1G9
- Clinical Site
-
-
Newfoundland and Labrador
-
Saint John's, Newfoundland and Labrador, Canada, A1A 4Y3
- Clinical Site
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 3C3
- Clinical Site
-
London, Ontario, Canada, N6H 5L5
- Clinical Site
-
Markham, Ontario, Canada, L3P 1X2
- Clinical Site
-
Newmarket, Ontario, Canada, L3Y 5G8
- Clinical Site
-
Peterborough, Ontario, Canada, K9J 5K2
- Clinical Site
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7K 2C1
- Clinical Site
-
-
-
-
-
Bad Bentheim, Germany, 48455
- Clinical Site
-
Berlin, Germany, 10117
- Clinical Site
-
Berlin, Germany, 10789
- Clinical Site
-
Berlin, Germany, 13595
- Clinical Site
-
Bochum, Germany, 44791
- Clinical Site
-
Darmstadt, Germany, 64283
- Clinical Site
-
Dresden, Germany, 01307
- Clinical Site
-
Frankfurt, Germany, 60590
- Clinical Site
-
Hamburg, Germany, 20246
- Clinical Site
-
Kiel, Germany, 24105
- Clinical Site
-
Luebeck, Germany, 23538
- Clinical Site
-
Mahlow, Germany, 15831
- Clinical Site
-
München, Germany, 80337
- Clinical Site
-
Münster, Germany, 48149
- Clinical Site
-
-
-
-
-
Dublin, Ireland, D04 T6F4
- Clinical Site
-
-
-
-
-
Bergen Op Zoom, Netherlands, 4624
- Clinical Site
-
Rotterdam, Netherlands, 3015 GD
- Clinical Site
-
-
-
-
-
Gdańsk, Poland, 80-214
- Clinical Site
-
Kraków, Poland, 31-033
- Clinical Site
-
Olsztyn, Poland, 10-341
- Clinical Site
-
Ossy, Poland, 42-624
- Clinical Site
-
Ostrowiec Świętokrzyski, Poland, 27-400
- Clinical Site
-
Poznań, Poland, 60-681
- Clinical Site
-
Warszawa, Poland, 02-507
- Clinical Site
-
Warszawa, Poland, 02-692
- Clinical Site
-
Wrocław, Poland, 50566
- Clinical Site
-
Wrocław, Poland, 51318
- Clinical Site
-
Łódź, Poland, 90-265
- Clinical Site
-
-
-
-
California
-
Fountain Valley, California, United States, 92708
- Clinical Site
-
Los Angeles, California, United States, 90056
- Clinical Site
-
-
Florida
-
Miami, Florida, United States, 33136
- Clinical Site
-
Ormond Beach, Florida, United States, 32127
- Clinical Site
-
Saint Petersburg, Florida, United States, 33709
- Clinical Site
-
Tampa, Florida, United States, 33613
- Clinical Site
-
-
Indiana
-
Indianapolis, Indiana, United States, 46250
- Clinical Site
-
-
Massachusetts
-
Beverly, Massachusetts, United States, 01915
- Clinical Site
-
Boston, Massachusetts, United States, 02215
- Clinical Site
-
-
Nebraska
-
Omaha, Nebraska, United States, 68144
- Clinical Site
-
-
New York
-
New York, New York, United States, 10003
- Clinical Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19103
- Clinical Site
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Clinical Site
-
-
Tennessee
-
Nashville, Tennessee, United States, 37215
- Clinical Site
-
-
Texas
-
Bellaire, Texas, United States, 77401
- Clinical Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participant is ≥18 years of age;
- Participant has been diagnosed with hidradenitis suppurativa as determined by the investigator and has a history of signs and symptoms of hidradenitis suppurativa dating back at least 6 months prior to the Screening Visit;
- Participant has a total abscess and/or inflammatory nodule (AN) count of ≥5;
- Participant has hidradenitis suppurativa lesions present in ≥2 distinct anatomical areas, at least one of which must contain single or multiple fistulas (i.e., be Hurley Stage II or III);
- Participant had an inadequate response to appropriate systemic antibiotics for treatment of hidradenitis suppurativa (or demonstrated intolerance to, or had a contraindication to, systemic antibiotics for treatment of their HS), in the investigator's opinion;
- Participant must be, in the opinion of the investigator, at both the Screening Visit and study treatment initiation, a suitable candidate for treatment with adalimumab per approved local product information.
Exclusion Criteria:
- Participants with known hypersensitivity to sonelokimab or any of its excipients;
- Participants with known hypersensitivity to adalimumab or any of its excipients;
- Participant has a draining fistula count of ≥20 at the Screening Visit;
- Participant has any other active skin disease or condition that may, in the opinion of the investigator, interfere with the assessment of hidradenitis suppurativa;
- Prior exposure to more than 2 biologic response modifiers;
- Participant has a diagnosis of ulcerative colitis or Crohn's disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: sonelokimab dose 1
Subjects randomized to this arm will receive assigned sonelokimab dosage regimen and placebo to maintain the blinding with adalimumab and placebo arms during the Treatment Period.
|
randomized treatment; parallel-group
|
Experimental: sonelokimab dose 2
Subjects randomized to this arm will receive assigned sonelokimab dosage regimen and placebo to maintain the blinding with adalimumab and placebo arms during the Treatment Period.
|
randomized treatment; parallel-group
|
Placebo Comparator: Placebo
Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and will be re-randomized to receive a sonelokimab dosage regimen during Part B.
|
randomized treatment; parallel-group
|
Active Comparator: adalimumab
Subjects randomized to this arm will receive adalimumab during the Double-Blind Treatment Period and will be reallocated to receive sonelokimab dosage regimen during Part B.
|
randomized treatment; parallel-group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hidradenitis Suppurativa Clinical Response 75
Time Frame: Week 12
|
Percentage of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75), where HiSCR75 is defined as at least a 75% reduction from baseline in abscess and inflammatory nodule (AN) count, with no increase from baseline in abscess or draining fistula count.
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hidradenitis Suppurativa Clinical Response 50
Time Frame: Week 12
|
Proportion of participants achieving HiSCR50
|
Week 12
|
Change in International Hidradenitis Suppurativa Severity Score System
Time Frame: Week 12
|
Change from baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) The IHS4 score is calculated as follows: number of nodules (multiplied by 1) plus the number of abscesses (multiplied by 2) plus the number of draining tunnels (multiplied by 4). A total score of 3 or less signifies mild, 4 to 10 signifies moderate and 11 or higher signifies severe disease. |
Week 12
|
Dermatology Life Quality Index (DLQI)
Time Frame: Week 12
|
Proportion of participants achieving a Dermatology Life Quality Index (DLQI) total score of ≤5 The DLQI produces a numeric score that can range from 0 to 30. A higher score indicates greater health-related quality of life impairment. |
Week 12
|
Reduction from Numerical Rating Scale (NRS30) in Patient's Global Assessment of Skin Pain (PGA Skin Pain)
Time Frame: Week 12
|
Proportion of participants achieving at least 30% reduction and at least 2-unit reduction from Baseline in Numerical Rating Scale (NRS30) in Patient's Global Assessment of Skin Pain (PGA Skin Pain) among subjects with Baseline NRS ≥3 The NRS is a numeric scale in which the respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). |
Week 12
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Prof. Kristian Reich, M.D., Ph.D. (equ.), MoonLake Immunotherapeutics AG
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- M1095-HS-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hidradenitis Suppurativa
-
Yale UniversityNot yet recruitingHidradenitis Suppurativa | Hidradenitis Suppurativa, Acne Inversa | Hidradenitis Suppurativa \(HS\)United States
-
Boehringer IngelheimRecruiting
-
Incyte CorporationRecruitingHidradenitis Suppurativa (HS)United States, Canada, Bulgaria, Italy, Spain, Germany, Poland, France, Australia, Denmark, United Kingdom
-
Novartis PharmaceuticalsAvailableHidradenitis Suppurativa (HS)
-
AbbVie (prior sponsor, Abbott)CompletedHidradenitis Suppurativa (HS)
-
InflaRx GmbHQuintiles, Inc.CompletedHidradenitis Suppurativa (HS)United States, Bulgaria, Canada, Denmark, France, Germany, Greece, Netherlands, Poland
-
Erasmus Medical CenterNot yet recruitingHidradenitis Suppurativa, Acne Inversa
-
Incyte CorporationRecruitingHidradenitis Suppurativa (HS)United States, Canada, Czechia, Spain, Germany, Poland, Netherlands, Belgium, France, Greece, Japan, Austria
-
Wake Forest University Health SciencesActive, not recruiting
-
Incyte CorporationRecruitingHidradenitis Suppurativa (HS)United States, Austria, Belgium, Canada, Germany, Poland, Spain, Australia, Denmark, France, United Kingdom, Japan, Bulgaria, Netherlands, Czechia, Greece, Italy
Clinical Trials on Adalimumab
-
PfizerCompletedHealthyUnited States, Belgium
-
PfizerCompletedHealthy SubjectsUnited States
-
AbbottCompletedArthritis, Juvenile IdiopathicUnited States, Belgium, Czech Republic, France, Germany, Italy, Slovakia, Spain
-
Shanghai Henlius BiotechCompleted
-
AbbottCompleted
-
Turgut İlaçları A.Ş.CompletedHealthy ParticipantsGermany
-
Mylan Inc.Mylan GmbHCompletedPsoriasis | Arthritis, PsoriaticBulgaria, Estonia, Hungary, Poland, Russian Federation, Ukraine
-
AbbottCompletedRheumatoid ArthritisSpain
-
AbbVie (prior sponsor, Abbott)CompletedRheumatoid ArthritisUnited States